Hydroxyfasudil
Star0
Identification
- Generic Name
- Hydroxyfasudil
- DrugBank Accession Number
- DB04707
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
- Weight
- Average: 307.368
Monoisotopic: 307.099062115 - Chemical Formula
- C14H17N3O3S
- Synonyms
- Hydroxy-fasudil
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism UcAMP-dependent protein kinase catalytic subunit alpha Not Available Humans UcAMP-dependent protein kinase inhibitor alpha Not Available Humans URho-associated protein kinase 1 inhibitorHumans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcarbose The therapeutic efficacy of Acarbose can be increased when used in combination with Hydroxyfasudil. Acetohexamide The therapeutic efficacy of Acetohexamide can be increased when used in combination with Hydroxyfasudil. Albiglutide The therapeutic efficacy of Albiglutide can be increased when used in combination with Hydroxyfasudil. Alogliptin The therapeutic efficacy of Alogliptin can be increased when used in combination with Hydroxyfasudil. Benzylpenicillin Hydroxyfasudil may decrease the excretion rate of Benzylpenicillin which could result in a higher serum level. - Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as isoquinolones and derivatives. These are aromatic polycyclic compounds containing a ketone bearing isoquinoline moiety.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Isoquinolines and derivatives
- Sub Class
- Isoquinolones and derivatives
- Direct Parent
- Isoquinolones and derivatives
- Alternative Parents
- Pyridinones / 1,4-diazepanes / Organosulfonamides / Benzenoids / Sulfonyls / Heteroaromatic compounds / Lactams / Dialkylamines / Azacyclic compounds / Organopnictogen compounds show 3 more
- Substituents
- 1,4-diazepane / Amine / Aromatic heteropolycyclic compound / Azacycle / Benzenoid / Diazepane / Heteroaromatic compound / Hydrocarbon derivative / Isoquinolone / Lactam show 15 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- isoquinolines, N-sulfonyldiazepane (CHEBI:43149)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- EYH4AU7P63
- CAS number
- 105628-72-6
- InChI Key
- ZAVGJDAFCZAWSZ-UHFFFAOYSA-N
- InChI
- InChI=1S/C14H17N3O3S/c18-14-12-3-1-4-13(11(12)5-7-16-14)21(19,20)17-9-2-6-15-8-10-17/h1,3-5,7,15H,2,6,8-10H2,(H,16,18)
- IUPAC Name
- 5-(1,4-diazepane-1-sulfonyl)-1,2-dihydroisoquinolin-1-one
- SMILES
- O=C1NC=CC2=C(C=CC=C12)S(=O)(=O)N1CCCNCC1
References
- General References
- Not Available
- External Links
- PubChem Compound
- 3064778
- PubChem Substance
- 46508609
- ChemSpider
- 2325236
- BindingDB
- 50027431
- ChEMBL
- CHEMBL1233300
- ZINC
- ZINC000013815406
- Therapeutic Targets Database
- DNC000754
- PDBe Ligand
- HFS
- PDB Entries
- 2erz / 2etk
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.875 mg/mL ALOGPS logP -0.15 ALOGPS logP -0.098 Chemaxon logS -2.6 ALOGPS pKa (Strongest Acidic) 12.64 Chemaxon pKa (Strongest Basic) 8.04 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 78.51 Å2 Chemaxon Rotatable Bond Count 1 Chemaxon Refractivity 81.01 m3·mol-1 Chemaxon Polarizability 31.07 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.997 Blood Brain Barrier + 0.8489 Caco-2 permeable - 0.6723 P-glycoprotein substrate Substrate 0.6958 P-glycoprotein inhibitor I Non-inhibitor 0.6954 P-glycoprotein inhibitor II Non-inhibitor 0.9625 Renal organic cation transporter Non-inhibitor 0.6941 CYP450 2C9 substrate Non-substrate 0.6207 CYP450 2D6 substrate Non-substrate 0.7713 CYP450 3A4 substrate Non-substrate 0.5402 CYP450 1A2 substrate Non-inhibitor 0.8454 CYP450 2C9 inhibitor Non-inhibitor 0.8777 CYP450 2D6 inhibitor Non-inhibitor 0.6308 CYP450 2C19 inhibitor Non-inhibitor 0.8427 CYP450 3A4 inhibitor Inhibitor 0.5648 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.846 Ames test Non AMES toxic 0.6497 Carcinogenicity Non-carcinogens 0.8222 Biodegradation Not ready biodegradable 0.956 Rat acute toxicity 2.3948 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9302 hERG inhibition (predictor II) Inhibitor 0.5474
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-0a4i-0009000000-00d33c1b37eb8ba2963f Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-0a4i-0019000000-25f4565a23bf0e2ef908 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-0a4i-0129000000-6aa07592a5df17fbe209 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-0a4i-0039000000-1c05947a586243c518c4 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-0a4i-9640000000-ceb4ab4e1826996e4f44 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-03dl-8921000000-047551a8cb31d84f7984 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 173.0064989 predictedDarkChem Lite v0.1.0 [M-H]- 159.75862 predictedDeepCCS 1.0 (2019) [M+H]+ 173.2901989 predictedDarkChem Lite v0.1.0 [M+H]+ 162.15465 predictedDeepCCS 1.0 (2019) [M+Na]+ 172.6900989 predictedDarkChem Lite v0.1.0 [M+Na]+ 168.29948 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Ubiquitin protein ligase binding
- Specific Function
- Phosphorylates a large number of substrates in the cytoplasm and the nucleus. Regulates the abundance of compartmentalized pools of its regulatory subunits through phosphorylation of PJA2 which bin...
- Gene Name
- PRKACA
- Uniprot ID
- P17612
- Uniprot Name
- cAMP-dependent protein kinase catalytic subunit alpha
- Molecular Weight
- 40589.38 Da
References
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Protein kinase a catalytic subunit binding
- Specific Function
- Extremely potent competitive inhibitor of cAMP-dependent protein kinase activity, this protein interacts with the catalytic subunit of the enzyme after the cAMP-induced dissociation of its regulato...
- Gene Name
- PKIA
- Uniprot ID
- P61925
- Uniprot Name
- cAMP-dependent protein kinase inhibitor alpha
- Molecular Weight
- 7988.435 Da
References
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]
3. DetailsRho-associated protein kinase 1
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Protein serine/threonine kinase activity
- Specific Function
- Protein kinase which is a key regulator of actin cytoskeleton and cell polarity. Involved in regulation of smooth muscle contraction, actin cytoskeleton organization, stress fiber and focal adhesio...
- Gene Name
- ROCK1
- Uniprot ID
- Q13464
- Uniprot Name
- Rho-associated protein kinase 1
- Molecular Weight
- 158173.545 Da
References
Drug created at September 11, 2007 17:49 / Updated at June 12, 2020 16:52